Home › Endometrial Cancer › Florida › Miami
Endometrial Cancer clinical trials in Miami, FL
16 studies for Endometrial Cancer are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- University of Miami School of Medicine, Miami
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecruitingObservational study
- Genoma Research, Inc., Miami
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RecruitingPhase 2
- Baptist Alliance MCI (Data Collection Only), Miami
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
RecruitingPhase 3
- Miami Cancer Institute, Miami
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Miami, Miami
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
RecruitingPhase 2
- University of Miami, Miami
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Sylvester Comprehensive Cancer Center, Miami
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
RecruitingObservational study
- Miami Cancer Institute Baptist Health South Florida, Miami
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
RecruitingPhase 1
- University of Miami, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Miami
- Research Site, Miami
Fasting InTervention for Endometrial Cancer
Recruiting
- University of Miami, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Miami
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer35 studies
- Prostate Cancer30 studies
- Obesity28 studies
- Ovarian Cancer24 studies
- Acute Myeloid Leukemia24 studies
- Overweight23 studies
- Metastatic Cancer22 studies
- Multiple Myeloma22 studies
- Lung Cancer22 studies
- Alzheimer's Disease21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.